Loading clinical trials...
Loading clinical trials...
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Conditions
Interventions
Placebo
Relamorelin
Locations
216
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Digestive Health Specialist of the South East
Dothan, Alabama, United States
Avant Research Associates
Huntsville, Alabama, United States
Synexus Clinical Research US, Inc.
Fountain Hills, Arizona, United States
Central Arizona Medical Associates
Mesa, Arizona, United States
Phoenix Clinical LLC
Phoenix, Arizona, United States
Start Date
September 29, 2017
Primary Completion Date
July 8, 2020
Completion Date
July 8, 2020
Last Updated
July 29, 2021
NCT07224321
NCT07340320
NCT07536516
NCT07232537
NCT07222137
NCT06513026
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions